Category Archives: Diabetes

Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes

BARCELONA, Spain, April 27, 2022 /PRNewswire/ -- Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European countries.

The new integrated AID system is being designed to connect Abbott's FreeStyle Libre 3 sensor, the world's smallest1 and most accurate2,3 continuous glucose monitoring sensor with readings every minute, to CamDiab's CamAPS FX mobile app, which connects with Ypsomed's mylife YpsoPump creating a smart, automated process to deliver insulin based on real-time glucose data. The connected, smart wearable solution is designed to continuously monitor a person's glucose levels and automatically adjust and deliver the right amount of insulin at the right time, removing the guesswork of insulin dosing.

"Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders," said Jared Watkin, senior vice president of Abbott's diabetes care business. "We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living."

"Poor glucose control leads to an increased risk of diabetes complications such as blindness, and heart and kidney disease. We want to help people with diabetes better manage their glucose through advanced technology. Our CamAPS FX, already approved in Europe, is a highly adaptive algorithm that when integrated with Abbott's sensor is being designed to communicate with Ypsomed's insulin pump to provide the optimal insulin dose, lifting the burden of managing a condition that is relentlessly unpredictable day and night," said Roman Hovorka, director of CamDiab Ltd.

"We are convinced that major challenges of society can only be addressed through partnerships. We are therefore proud to expand our partners and connectivity to offer more freedom of choice in managing diabetes. When combined our mylifeYpsoPump with the FreeStyleLibre 3 system and CamAPS FX advanced adaptive hybrid closed-loop app, we will be able to deliver an additional compact and lightweight AID system that is discreet and simple to use," said Simon Michel, chief executive officer of Ypsomed.

The companies intend to complete development by end of 2022 with commercial availability expected thereafter.

About AbbottAbbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at http://www.abbott.com, on LinkedIn at http://www.linkedin.com/company/abbott-/, on Facebook at http://www.facebook.com/Abbott and on Twitter @AbbottNews.

About CamDiabCamDiab Ltd is a digital health and personalized medicine company focused on the design, development, and commercialization of its world leading, interoperable CamAPS FX closed loop app. The CamAPS FX is designed to use adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycaemic control. Since its founding in 2019, its mission has been to help people with type 1 diabetes and their families live better lives. For further information, visit http://www.camdiab.com or follow CamDiab Ltd and its products on Facebook, LinkedIn, and Twitter @CamAPS_FX.

About YpsomedYpsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years' experience. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors, pump systems and software solutions for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brands mylifeDiabetescare directly to patients or via pharmacies and hospitals as well as under YDSYpsomed Delivery Systems in business-to-business operations with pharmaceutical companies. The company is headquartered in Burgdorf, Switzerland, and has a global network of production facilities, subsidiaries and distribution partners employing a staff of around 1,900 employees worldwide. http://www.ypsomed.com

1 Among patient-applied sensors. Data on file, Abbott Diabetes Care.2 FreeStyle Libre 3 User Manual.3 Data on file. Abbott Diabetes Care, Inc. Comparison based on publicly available information.

SOURCE Abbott

For further information: Abbott Media: Anita de Groot, anita.degroot@abbott.com, +31 (0)88 82 22 643, Samantha Thai, samantha.thai@abbott.com, +1 510-239-2765, Abbott Financial: Mike Comilla, mike.comilla@abbott.com, +1 202-213-5129, Ypsomed Media: Thomas Kutt, thomas.kutt@ypsomed.com, +41 34 424 35 55

Read more from the original source:
Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes - Press Releases

Seattles Benaroya Research Institute (BRI) has landed $17.1 million in funding to assess why respiratory infections hit some people particularly hard, to explore new ways of treating type 1 diabetes, and other efforts.

The institution announced the funding, from the U.S. National Institutes of Health, on Thursday.

The study of respiratory infections will be powered with a $11.4 million grant for five years. Researchers will assess why children with asthma, allergies or obesity are particularly vulnerable to severe respiratory infections. They will also ask why adults with chronic inflammatory or autoimmune diseases are at increased risk of severe effects from such infections.

BRI investigators Carmen Mikacenic andMatt Altman will lead the multi-institution study, which will profile how patients respond to infection at the molecular and cellular level. Questions include which immune cells are activated, and how proteins, genes and other cellular molecules respond to infection.

Ultimately, researchers may be able to correlate such information with clinical outcomes and identify potential therapies. They will share their data with the Human Immunology Project Consortium, a network of researchers characterizing the immune system.

This research will help contribute to a baseline understanding of how the immune system responds to infection in these understudied populations, said Mikacenic in a press release.

A second, $3.9 million grant, will use human cells and mouse models to investigate new ways to treat type 1 diabetes, which results from autoimmune destruction of insulin-producing cells in the pancreas. Researchers will engineer protective regulatory T cells to target the insulin-producing cells, preventing their destruction and promoting their health.

The four-year diabetes project will be led by BRI researchers Eddie James and Jane Buckner, who is the institutions president, as well as Seattle Childrens Research Institute researcher David Rawlings. Rawlings is a co-founder of preclinical biotech company Gentibio, which is also developing regulatory T cell therapies for type 1 diabetes and other autoimmune and inflammatory conditions.

The new studies will take the approach further, targeting the pancreatic cells only when they are stressed, and delivering molecular cargo directly into them support their health.

We aim to uncover ways to promote healthy islet function and protection, said Buckner in the press release, referring to groups of insulin producing cells.

Four other BRI projects received about $475,000 each from the NIH, including studies on multiple sclerosis, autoimmunity, Crohns disease, and lung fibrosis in COVID-19. BRI is known for its focus on diseases of the immune system.

Follow this link:
Studies on respiratory infections, type 1 diabetes, boosted with $17M to Benaroya Research Institute - GeekWire

Thiazolidinediones may change metabolic patterns and contribute to weight gain.

The likelihood of developing type 2 diabetes is increasing at an alarming rate, along with the average daily intake of simple carbohydrates. Consequently, insulin is released to counteract the surge in blood sugar; however, over time, the body grows resistant to its own insulin and blood glucose levels remain elevated.

This onset of type 2 diabetes is often treated using the class of medications known as thiazolidinediones. These compounds activate the fat cell protein peroxisome proliferator-activated receptor gamma (PPARgamma), which is endogenously existent in 2 forms, PPARgamma1 and PPARgamma2. However, they are notoriously known for changing metabolic patterns and contributing to weight gain.

In a study conducted at the Perelman School of Medicine at University of Pennsylvania, senior author Mitchell Lazar, MD, PhD and his team uncovered the differences between the downstream actions of both PPARgamma forms.1

The study involved limiting the amount of PPARgamma1 or PPARgamma2 proteins in 2 separate groups of mice to notify the significance of activating only 1 subtype.

The administration of thiazolidinediones led to anti-diabetic effects in both groups of mice, but only the group with PPARgamma1 deficiency did not gain weight.1

According to Lazar,1 in this group, the PPARgamma protein is largely present as PPARgamma2, which initiated a different downstream gene activity that did not adversely change metabolic patterns. Lazar and his team are eager to explore methods in using thiazolidinediones to selectively activate PPARgamma2 to allow anti-diabetic benefits without the risk of weight gain.

Previous studies regarding PPARgamma1 and PPARgamma2 show that PPARgamma2 is primarily present in adipose tissue to downregulate the expression of fat proteins, such as TNF-alpha, that are linked to obesity.2 A study conducted by the Royal Pharmaceutical Society indicates an increase in fatty acid reuptake and formation of high-density cholesterol following selective activation.

The subsequent decrease in free fatty acids, low density lipoprotein, and triglycerides reduce the likelihood of gaining weight that is typically associated with thiazolidinediones. Due to insulin resistivity, metabolic hormones like adiponectin and leptin are dysregulated, contributing to increased food intake and fat storage.

PPARgamma2 agonists increase selective adipocyte expression to increase secretion of adiponectin and thereby increase insulin sensitivity. As Saraf et. al outlines,2 the alteration in gene activity by PPARgamma2 activation allows for both glucose disposal and regulation of adipocyte expression in insulin-sensitive polypeptides.

A closer look at the differences between PPARgamma1 and PPARgamma2 differentiates their gene pathways; PPARgamma2 has a polymorphic Pro12Ala variant.2 This isoform is the key difference in preventing weight gain through reducing high fat-feeding and improving adipocyte metabolism.

In this way, PPARgamma2 allows for greater adipocyte regulation that is typically absent in type 2 diabetes. Selective activation of PPARgamma2 fat protein can potentially decrease adverse metabolic effects related to thiazolidinediones.

References

See more here:
Activating Protein Subtype May Lower Common Adverse Effects Associated with Thiazolidinedione Medications for Diabetes - Pharmacy Times

Tucker Pillsbury is in love. The details are none of our business, of course, but under his stage name, Role Model, he's got an awful lot to say about it.

On Role Model's first studio album, RX, there's plenty of discussion to be hadabout love, about pain, about sin, about forgiveness. And the man behind an album containing tracks like "die for my b**ch," "masturbation song" and "stripclub music" is feeling pensive about life's biggest questions.

Ahead of live shows at Coachella and the kick-off of his first world tour, Role Model sat down with Newsweek to catch us up on where he's at and where he's going.

When we're speaking, your album, RX, came out just a few days ago. How are you feeling?

I'm good. I finally got to digest it a little bit. But then we just yesterday jumped straight back into rehearsals. So now I'm like, back off my phone and playing the music live and looking forward to getting on stage again.

Are you sort of feeling disbelief about the thing being done? I know when I'm working in a creative space, there's a point at which I have to force myself to let it go. Have you reached that point? Or would you still be messing with it if you were able to?

I thought I would cry when it came out! I thought I was gonna have this emotional thing. But maybe it was because my friends all flew out here for the release and everything. And so I was like, with people the whole time, and I think I didn't really get to digest the whole thing until the next day.

But it feels incredible. I mean, it was two years in the making. And it's my first album after being signed to a label for, I don't even know, three years? So it's been more than a long time coming. And I'm happy that I waited and happy that we did it the way we did it.

Did this production feel different than your past work in some way?

For sure. I love my old music. And I love performing it of course, but I [re-]listened to those songs and I'm like... what am I even talking about? Like, there's no cohesive story or like, there's themes and stuff, but it's spill of consciousness.

Whereas when we started this album, I really wanted every song on this album to feel complete, like a complete thought, a complete story. I wanted to be so picky about every word that we put in.

So that was really good. And then also just learning how to use my voice... five-part, six-part harmonies, which I [have] never been able to do in my life. I'm not that musical.

So yeah, I hope it feels like a step up and in every way, hopefully.

You tweeted that you think this album is going to be "insane" live. It is such an intimate and personal albumat times you're whispering into the microphone. Do you change the way you think about the music when you're thinking of performing it in front of a crowd like Coachella?

100 percent. These shows, I always say it's pop music, played like rock music, performed like rap music. When you come to the shows I want the energy of a rap show.

Those lyrics that I'm whispering into the mic are now being yelled. Like, screamed. I love the energy. I love jumping around and it's hard to whisper and be like jumping up and down at the same time.

I would love to hear you talk a little bit about your influences on this record. I will say that there's one that comes to mind for me immediately, and that is Mac Miller. Particularly on "If Jesus Saves," I very much hear "Divine Feminine," that era of Mac's work.

And I know that Mac is, of course, really, really instrumental in your career. Was he on your mind? Were there other artists that you were looking to for inspiration?

I think, inevitably, Mac is always going to be an influence, even if you can't hear it in the songs. Almost every time I'm in the studio, it's one of those things where you ask yourself if he would hate this, or if he would be, like, bobbing his head to it. And I always do that.

Even outside of music, there's stuff where I weirdly check in with him. That sounds like I'm super spiritual. But it's like, he's one of those people where his approval was everything. If he was like, going like this [head nod and smile] while you're playing a song... Yeah, he's a huge influence.

And like every other artist in the world right now, what I listen to is so all over the place. I think everyone is that way now, because we're just exposed to everything. So like, I'm listening to Drake and Rihanna, and then Neil Young, Van Morrison, and Kacey Musgraves, and Mac. It's all over the place. So no matter what that's gonna seep its way into my music.

The only thing I really tried to keep cohesive is the lyrics and the way I talk. I want people to be like, "Oh, yeah, that's a Role Model song." Because who would else be like talking about touching themselves to a loved one like me?

There's an interesting spiritual and religious undercurrent to RX. You're clearly working on making sense of a lot.

I'm not a religious person, but I just think using all these religious visuals [is] not a new thing, I know every artist is doing it. I just felt like for my personal story... there were just a lot of easy connections that I was finding with the way someone is on their knees, a breaking point, finding God, an epiphany or a miracle. I sound dramatic. But like that's genuinely what it felt like. I had never experienced falling in love. So it hit me like a train. And it really did feel like a drug or something heavenly.

And I have no idea what that feels like to find God or anything, but I just think there's connections there. And so there's religious metaphors throughout the album. I think I probably said "Jesus" a little too much in the whole album.

Has that given you trouble at all?

Um, honestly, yeah, I lost some followers with that "If Jesus Saves" song. In the beginning. But I think once the album came out, I think people maybe understand a bit more. Life is funny. And people are kind of understanding the message, which is good.

You are kicking off a world tour on the 13th of April, and then we will be at Coachella. How are you feeling about that? A world tour is kind of a big deal.

I know. I'm trying not to think about it too hard. I'm so excited to get on the road obviously. And like, Coachella is incredible. All the festivals are incredible, but I'm trying not to think about the fact that I'm going to be gone that long.

But I can't wait, and I miss just hearing people in the crowd. It's just very inclusive, and it's like we're all kind of doing it together. It's my favorite thing in the world.

You've talked a lot about being diabetic, and how being on the road is exhausting. It's exhausting for a lot of people who don't have to deal with that. So what would you say to a little diabetic kid who was thinking about getting into music? Is it too much? Is it manageable?

[pauses] How do I say this? It's hell. Like, it feels incredible, once you get to a point where [you're] like, wow, I'm doing it! If I stopped now, like, there's no example to be set for kids.

Honestly, diabetes is the scariest part of touring. I'm not concerned about forgetting lyrics anymore. I'm not concerned about like, us having technical issues on stage. It's more like, okay, how am I going to survive for these two months? I do everything very independently. It's like, hard to teach people in a short amount of time everything that goes into it, but yeah, it's a lot.

But I would say to any kid with diabetes: please don't let that limit you. When I was a kid, I remember going home to my doctor and my endocrinologist. And she was like, asking me how I'm doing and what I'm doing and what I'm interested in, college and everything. And I told her, I was really interested in music all of a sudden, and I was very passionate about it at the time.

She basically told me that I should probably find a more secure job, because it's a very expensive disease. And I remember driving home crying my eyes out. That wrecked me. But once you can kind of digest that and think about that and think about the person that just said that to your face and where they are? All you want to do is just prove them wrong.

So I guess I have a little bit of competitiveness in me. But yeah, I would just say to any kid, no matter what anyone says to you... you have the whole world in your hand.

Last question: what was the last song you had stuck in your head?

Wow. Oh, that new Jack Harlow song. It's the hook.

Newsweek's continuing Coachella coverage can be found online at newsweek.com and on On Beat, available wherever you get your podcasts.

Go here to read the rest:
Role Model on Checking in With Mac Miller and Touring With Diabetes - Newsweek

Newswise BOSTON An estimated 25 percent of people older than 65 have type 2 diabetes, a condition in which the body cannot produce enough insulin to effectively manage blood sugar. Insulin plays an important role in the brain, and people with prediabetes and diabetes are at increased risk of Alzheimer's disease and cognitive decline. Delivering insulin to the brain intranasally atomized and sprayed through the nose has been shown to improve verbal memory and has emerged as a potential treatment for cognitive decline in the elderly.

Now, a team of scientists at Beth Israel Deaconess Medical Center (BIDMC) have assessed the long-term effects of intranasal insulin (INI) on cognition and on gait in people with and without type 2 diabetes mellitus. MemAID, a phase 2 randomized controlled clinical trial, provided evidence that intranasal insulin increased the walking speed, increased cerebral blood flow and decreased plasma insulin in participants with type 2 diabetes, while it improved decision making and verbal memory in trial participants without the disease and those with pre-diabetes. The findings, published in the Journal of Neurology, suggest intranasal insulin should be further tested for its possible utility as a treatment for type 2 diabetes as well as a treatment for age-related functional decline.

Walking speed is an important clinical predictor of well-being in the elderly that correlates with cognitive decline, hospitalizations, disability and death, said corresponding author Vera Novak, MD, PhD, of the Department of Neurology at BIDMC and an associate professor of neurology at Harvard Medical School. At baseline, participants with diabetes walked slower and had worse cognition than the participants without diabetes, who served as a clinical reference for normal aging population.

Novak and colleagues at BIDMC and BWH enrolled 223 participants ages 50 to 85-years-old with and without diabetes, and assessed their normal and dual task walking speeds, attention, memory and executive function and mood using a battery of validated tests. Half of the participants with diabetes (n=51) and half without diabetes (n=58) were treated with insulin, delivered intranasally via an electronic atomizer once daily. A double blinded trial, the other participants were given an inactive placebo (sterile saline) that was also delivered intranasally.

After 24-weeks of treatment participants with diabetes who received INI had faster walking speeds during treatment and post-treatment than participants with diabetes who received placebo. The INI-treated participants with diabetes also demonstrated increased cerebral blood flow in the frontal lobe, and lower plasma insulin and insulin resistance compared to the placebo group, while the INI-treated participants without diabetes showed improved decision making and verbal memory. Combined, the INI-treated participants both with and without type 2 diabetes demonstrated faster walking and better executive functioning and memory, with those with pre-diabetes showing the most marked improvements in decision making and verbal memory.

The consistency of the trends in the data showing better performance on walking speed and cognition for INI-treated participants, especially in those with pre-diabetes, carries great implication for potential early intervention using INI in this population to prevent or slow down the progression toward Alzheimer Diseases related dementias, said Long Ngo, PhD, senior author of the study and co-director of Biostatistics Division of General Medicine at BIDMC , as well as associate professor of medicine and biostatistics at Harvard Medical School, and Harvard T.H. Chan School of Public Health. With 96 million adult Americans, and increasing number of younger people having pre-diabetes, this finding on the beneficial effect of INI deserves more attention and definitive confirmation in a larger trial.

The treatment was not associated with any serious or moderate adverse events.Intranasal insulin treatment was safe in participants with type 2 diabetes treated with subcutaneous insulins.

Co-authors included Christos S. Mantzoros, MD, Dsc, Vasileios Lioutas, MD, Stephanie Buss, MD, Faizan Khan, MD, and Laura Aponte Becerra, MD, of BIDMC; Peter Novak, MD, PhD Site Principal Investigator of Brigham and Womens Hospital; Regina McGlinchey PhD- Site Principal Investigator, and Catherine B. Fortier, PhD, of VA Boston Healthcare System and Harvard Medical School; and Weiying Dai, PhD, of State University of New York, Binghamton.

Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIIDDK) under award number R01DK103902, FDA IND 107690) and with support from Harvard Catalyst - The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health award UL1TR002541) and financial contributions from Harvard University and its affiliated academic health care centers. This research study was supported with a study drug from Novo Nordisk, Inc., through an independent ISS grant (ISS-001063) toNovak. Safety sub-study was supported with CGM monitoring devices and supplies from Medtronic Inc., through an independent grant NERP 15-031 to V. Novak. Novo Nordisk, Inc., and Medtronic, Inc., reviewed the manuscript, but had no participation in data analysis, manuscript preparation or submission decision.

Novak, McGlinchey, Fortier, Dai, Khan and Aponte Becerra report no disclosures relevant to the manuscript. Mantzoros provided consultations for Coherus, AltrixBio, California Walnut Commission, Genfit, Regeneron, Ansh, Amgen, Intercept and Aegerion. Mantzoros has provided educational services through Elsevier, CMHC, TMIOA (all unrelated to this project since 2015 through 2020). Mantzoros provided consultations for Novo Nordisk, Inc., on Obesity Advisory Board, and has received grant support through BIDMC which could be considered as related to this project, given that Novo Nordisk, Inc. provided medication. Ngo provided consultation to the Radiological Society, the Journal of Cardiovascular Magnetic Resonance, Five Island Consulting LLC, and to Vinmec Inc. between 2015 and 2020. For a full list of disclosures, please read the study at the Journal of Neurology.

About Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.

BIDMC is the official hospital of the Boston Red Sox. For more information, visitwww.bidmc.org.

Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,800 physicians and 36,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.

Follow this link:
Insulin Spray Improved Gait, Cognitive Function in Patients with and Without Type 2 Diabetes, Clinical Trial Shows - Newswise

According to the Centers for Disease Control and Prevention, "37.3 million Americansabout 1 in 10have diabetes. About 1 in 5 people with diabetes don't know they have it." While diabetes is manageable, if left untreated, diabetes can become a serious condition that can result in blindness, nerve damage, heart disease, kidney failure and amputations. Keeping diabetes in check is key to living a healthy life. Eat This, Not That! Health talked with experts who explain what the risk factors are for diabetes, how to help get it under control and what symptoms to watch out for. Read onand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

Dr. Bayo Curry-Winchell, Urgent Care Medical Director and Physician, Carbon Health, and Saint Mary's Hospital says, "If you need to use the restroom more than usual for example (waking up in the middle of the night) and it's not associated with increased fluid intake this could be a sign of diabetes. When your body has an elevated amount of glucose the kidneys respond by increasing urination to help remove the excess glucose."

"If you start to experience numbness, sharp pains, tingling in your hands, arms, legs or feet often referred to as neuropathy, this can be a sign of diabetes. This is caused by an increase in blood sugar (glucose) which affects the amount of blood flowing to your organs and muscles affecting nerves throughout the body," Dr. Curry-Winchell explains.

Dr. Curry-Winchell states, "Unfortunately, elevated blood sugar does not mean more energy. The body is not able to use the excess sugar, instead you feel tired and "run down" even after a good night's rest."

Dr. Curry-Winchell shares, "Diabetes can affect many aspects of your daily life. The disease has the potential to cause harm or damage to several organs such as the eyes, brain, heart, kidneys, and skin. When diabetes is not under control, it can be disruptive to your life and impact your ability to perform personal and professional activities."

RELATED: Habits Secretly Increasing Your Pancreatic Cancer Risk, Say Physicians

According to Dr. Curry-Winchell, "The reason is multifaceted and involves a decrease in physical activity and increased consumption of high calorie foods which leads to weight gain ultimately increasing your risks for developing diabetes. The pandemic has also played a role. For almost two years people were asked to stay home which led to less exercise, isolation and adopting unhealthy coping skills with food or sedentary hobbies."6254a4d1642c605c54bf1cab17d50f1e

Dr. Nisha Jayani, a board-certified endocrinologist with Paloma Health shares, "Being overweight and being physically inactive are two major risk factors for type 2 diabetes. By eating better and getting regular exercise, you can help to prevent type 2 diabetes.You should avoid eating processed meats, white rice, and sugar-sweetened beverages. Instead, load up on nutrient-dense goodness like leafy green veggies, fruits rich in anthocyanins, quality dairy products, nuts, and legumes."

RELATED: Doing This After Age 60 is "Unhealthy," Say Physicians

Dr. Jayani states, "Eating a Mediterranean-style diet, a diet rich in fish, vegetables, fruits, whole grains, beans, nuts and seeds, and olive oil, can be beneficial for the long-term prevention of diabetes." Dr. Jayani adds, "Aerobic exercises like walking, swimming, or riding your bike can help decrease your blood glucose levels. I recommend 30 minutes of moderate aerobic activity a few days a week to help prevent diabetes in the long term."

Excerpt from:
Sure Signs You Have Diabetes, Say Physicians Eat This Not That - Eat This, Not That

Almost four million people in the UK have diabetes, but thousands of cases are still undiagnosed.

Figures from the Diabetes and Wellness Foundation estimates that 1,000,000 adults have type 2 diabetes but do not know it.

Type 2 diabetes is far more common than Type 1, and accounts for around 90% of all adult cases in the UK.

The lifelong condition is caused by problems with the production of insulin in the body and is often linked to being overweight or inactive, or having a family history of type 2 diabetes.

It causes the level of glucose in the blood to become too high and can lead to a variety of serious health conditions, such as heart disease or a stroke.

Many people have the condition without realising as symptoms do not necessarily make you feel unwell, making the disease difficult to spot.

However, there are a few telltale signs to look for that could be a warning sign of type 2 diabetes.

What are the symptoms?

Two common symptoms of high blood sugar - also known as hyperglycaemia - can be evident in the mouth. These include a dry mouth and a breath that smells fruity, according to the NHS.

Other symptoms that could be a sign of type 2 diabetes include:

Symptoms of hyperglycaemia in people with diabetes tend to develop slowly over a few days or weeks, and in some cases symptoms will not appear until blood sugar levels are very high.

Hyperglycaemia symptoms can also be caused by undiagnosed diabetes, so the NHS advises seeing a GP if this applies to you.

What can cause high blood sugar?

A variety of factors can trigger an increase in blood sugar level in people with diabetes. Typically this can include:

How is it treated?

Most people will need medicine to control their type 2 diabetes. This will help to keep blood sugar levels as normal as possible to prevent further health problems and may need to be taken for the rest of your life.

A healthy diet and keeping active can also help to manage your blood sugar levels.

The NHS recommends eating a wide range of foods, including fruit, vegetables and starchy foods like pasta, and keeping sugar, fat and salt to a minimum. Around 2.5 hours of physical activity is also advised per week.

There is evidence that eating a low-calorie diet (800 to 1,200 calories a day) on a short-term basis (around 12 weeks) can help with symptoms of type 2 diabetes, and some people have found that their symptoms go into remission.

However, a low-calorie diet is not safe or suitable for everyone with type 2 diabetes, such as those who need to take insulin, so it is important to seek medical advice before going on this type of diet.

Originally posted here:
2 symptoms of high blood sugar in the mouth that may indicate diabetes - NationalWorld

In 1986, Jill Norris had a Bachelor of Arts degree in biology in hand and pondered what to do next. She decided to pursue a doctorate in epidemiology and applied to a few schools. An invitation from a renowned figure in the field not only cemented her decision but also set her on a lifelong professional path to an elite position among her peers and now, international recognition.

Norris hadnt anticipated the door that opened. She was still mulling her doctoral choices when the late Dr. Ronald LaPorte, an epidemiologist at the University of Pittsburgh, urged Norris to join his program. LaPortes studies focused on type 1 diabetes, the autoimmune disease that destroys the bodys ability to produce the glucose-regulating hormone insulin. LaPorte needed investigative allies and told Norris he had a position for her, should she choose to accept.

Norris didnt know much about type 1 diabetes, but took LaPorte up on his offer anyway.

I liked him so much and loved his group, she recalls. I walked into a wonderful situation where I learned the story behind type 1 diabetes and so many things about it that I hadnt even been aware of.

Norris embarked initially on a project to study the protective effects of breastfeeding against type 1 diabetes. It set the stage for a career dedicated to probing the mysteries of autoimmune diseases not only diabetes, but also rheumatoid arthritis, celiac disease, multiple sclerosis and lupus. Her contributions include extensive funded research, hundreds of published peer-reviewed papers, wide-ranging committee work, and a long commitment to mentoring students. She has chaired the Department of Epidemiology in the Colorado School of Public Health since 2011.

The early days in Pittsburgh set her course. From the very beginning, my work was on nutrition and type 1 diabetes. Amazingly, Ive never strayed too far from that, Norris said.

A little more than three decades after she received her doctorate in Epidemiology from Pitt, Norriss unflagging work on type 1 and type 2 diabetes has earned a notable honor. She is the 2022 recipient of the American Diabetes Associations Kelly West Award for Outstanding Achievement in Epidemiology, which recognizes significant contributions to the field of diabetes epidemiology.

ADA Award Winner Reusch, MD, Makes the Most of CU Anschutz Collaborations

Jane E.B. Reusch, MD, professor of medicine, bioengineering and biochemistry in the Division of Endocrinology, Metabolism and Diabetes at the University of Colorado School of Medicine and associate director of the Ludeman Family Center for Womens Health Research at the University of Colorado Anschutz Medical Campus, is the recipient of the2022 Albert Renold Award from the American Diabetes Association (ADA). She is based in the division of endocrinology, metabolism and diabetes at CU Anschutz and the endocrine section at the Rocky Mountain Regional VA Medical Center.

This award is presented to an individual whose career is distinguished by outstanding achievements in the training and mentorship of diabetes research scientists and in the development of communities of scientists to enhance diabetes research.

Reusch started her career in as a physician scientist doing cell biology research on the nuclear aspects of insulin resistance and how that affects diabetes and its complications. Propelled by a desire to help patients, including her father, who suffered from the disease, Reusch partnered with Judy Regensteiner, PhD, director of the Ludeman Family Center for Womens Health Research, to understand how diabetes leads to impairments in functional exercise capacity.

Functional exercise capacity is measured by exercising as hard as you can. People with type 1 or type 2 diabetes already have about a 20% defect in their maximal exercise capacity. Maximal exercise capacity is the most potent predictor of life expectancy, so it is serious that it is impaired in people with otherwise uncomplicated diabetes. Reusch and Regenstiener identified that insulin resistance, blood-flow abnormalities, cardiac dysfunction and skeletal muscle dysfunction collude to give diabetes patients lower functional exercise capacity.

She also collaborates with researchers at the Childrens Hospital such as Kristen Nadeau, MD, MS, who won the Outstanding Scientific Achievement Award from the ADA in 2021, the Center for Bioengineering and the Barbara Davis Center for Diabetes.

Reusch said CU Anschutz is the place where you should be doing diabetes research. We have a great collaborative environment, brilliant scientists and a growing infrastructure to support innovation.

Reusch also mentors students, post-doctoral fellows, and junior, mid-level and senior faculty. One of the first graduate students she worked with was a trainee of Jill Norris, PhD, MPH, at the Colorado School of Public Health.

She is dedicated to training the next generation of scientists and to the strengthening the clinical-translational workforce. At the core of her world-class NIH, VA and ADA-funded translational diabetes research program is the mission to recruit, train and retain new translational scientists to the diabetes workforce, particularly focused on womens health and sex as a biological variable.

I love the opportunity to be a doctor, to be an educator and to ask questions and contribute to discovery in research, Reusch said. I have the world's best job, so of course I want other people to have it too.

- Kiley Kudrna

Norris will discuss her work, which includes not only her pioneering studies into the genetic and environmental links with type 1 diabetes and other autoimmune diseases, but also mentoring and volunteering, at the ADAs 82nd Scientific Sessions in New Orleans June 3-7.

That effort spans decades of contributions to long-term studies of diabetes. These include, among many others, nearly 30 years of service with the NIH-funded Diabetes AutoImmunity Study in the Young (DAISY), working with her colleague Dr. Marian Rewers, executive director of the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus. The aim: explore the ways that a persons genetics and environment may combine to drive type 1 diabetes.

In addition, Norris is a longtime investigator on The Environmental Determinants of Diabetes in the Young (TEDDY) Study (also NIH-funded, with the Barbara Davis Center one of six study sites). She has co-chaired its Diet Committee since 2002.

The TEDDY initiative is responsible for screening well over 400,000 kids with type 1 diabetes in the United States and Europe. It identifies newborns at genetic risk for the disease and follows them for 15 years in the hopes of deciphering the causes of type 1 diabetes and how they might be addressed with strategies like modifying diet.

For example, some studies suggest that low levels of vitamin D and omega 3 fatty acids may increase the risk of type 1 diabetes. More work is needed, but the studies open the possibility of targeted dietary interventions aimed at those who would most benefit, Norris said.

In a summary of her research, Norris underscored her strong belief that genetics predisposes individuals to type 1 diabetes and other autoimmune disorders, such as celiac disease, but also that they dont predetermine outcomes.

It has become clear that without considering both the genetic and environmental risk factors of diseases, we may never come to a complete understanding of their etiology and potentially, their public health impact, she wrote.

Asked to elaborate on the point, she said, I like to think that we can work within a persons genetic predisposition to decrease the burden of the presence of the disease.

Norris cautioned, however, that the genetic-environmental connection is complicated and much effort remains to untangle it. For example, some studies indicate that the potentially protective power of foods rich in vitamin D, omega 3 fatty acids and other biomarkers may hinge not only on eating more of them but also on an individuals genetic ability to turn them into something that has protective influence. What turns one person on and another not, in effect, is a big question to be answered.

The TEDDY study therefore points to the importance of finding the kids whose genetic makeup make them the best candidates for interventions, informing them of the reasons to make changes in their diets and lifestyles, and making sure those changes fit in the fabric of their everyday lives, Norris said.

My goal would be to create diets that are attainable and sustainable, she said. We dont want diets where people totally eliminate one thing. You want to give people options. Its not all about one good thing or one bad thing.

Going forward, Norris said she also anticipates further research aimed at preventing autoimmune diseases from occurring. That requires not only broad screening to identify at-risk individuals but also having safe interventions at the ready for those who need them, she said.

In Norriss view, the Kelly West honor puts her name among the many epidemiologists who helped to spur her career and whose friendship and collegiality she values.

When I look at the long list of winners before me, many of them were my mentors and many others are current colleagues and friends, she said. To be part of that fabulous community means so much to me.

Her connection with LaPorte illustrates the depths of her roots in that community. LaPorte, Norriss original entre to epidemiology and Type 1 diabetes research, was one of the original Kelly West Award recipients in 1988. He also was instrumental in driving development of type 1 diabetes registries around the world, including one established in Pittsburghs Allegheny County.

His work, as well as that of Jan Dorman, LaPortes wife and Norriss co-mentor while at Pittsburgh, dovetailed nicely with Norriss budding career when she moved to Colorado in 1990 to take a position as assistant professor in the Department of Preventive Medicine and Biometrics Section of Epidemiology and Community Health in the University of Colorado School of Medicine. She worked with Dr. Richard Hamman, a fellow epidemiologist who was to become the founding Dean of the Colorado School of Public Health in 2008. In 1984, Hamman had also launched a type 1 diabetes registry to identify and collect data on all children in Colorado diagnosed with the disease.

Hamman and his colleagues published the influential San Luis Valley Diabetes Study of residents in two deeply rooted southern Colorado communities. The study concluded that type 1 diabetes was a major chronic disease problem for persons of Hispanic ethnicity in the San Luis Valley.

Norris worked with Hamman and Dr. Julie Marshall, now Professor Emeritus in the Department of Epidemiology at ColoradoSPH, studying the genetic and environmental epidemiology of type 2 diabetes among families in the San Luis Valley. In her work, she relied on the population from Hammans San Luis Valley Diabetes Study and studied their family members in a community-run research clinic Hamman established.

I have a soft spot for the San Luis Valley, said Norris, recalling how her studies deepened her appreciation for its people, whose descendants have spread far beyond its geographical bounds. I learned there how to conduct research, not just outside our front door.

The experience in the San Luis Valley also placed Norris as one of many foundational pillars in the Rocky Mountain Prevention Research Center, launched in 1998 by Hamman and Marshall and now directed by Dr. Jenn Leiferman, professor and Chair in ColoradoSPHs Department of Community & Behavioral Health which continues to maintain strong ties in southern Colorado.

Having gained so much knowledge from others, Norris is intent on extending the same commitment to fellow contributors to epidemiology.

Mentoring is incredibly important to me, she said. Mentoring can take many forms. It can be students but it can also be your fellow faculty. A number of students that I have worked with in the past have grown and while they may not be working on diabetes, they have developed other exciting and important areas of research. I cant imagine being at an institution that didnt emphasize teaching.

Guest contributor: Tyler Smith for the Colorado School of Public Health

Follow this link:
American Diabetes Association Honors Two Outstanding CU Anschutz Researchers - University of Colorado Anschutz Medical Campus

Dr. Lucy Mastrandrea (left) and Dr. Kathleen Bethin (right).Photo credit: Jacobs School of Medicine and Biomedical Sciences.

Program funded by a $1.4 million grant from The Leona M. and Harry B. Helmsley Charitable Trust will focus on expanding access to virtual diabetes care.

NEW YORK, NY APRIL 19, 2022 The majority of children living with Type 1 diabetes in the United States are not meeting their hemoglobin A1c (HbA1c) goals, a measure of how much sugar is in the blood, and a leading indicator of both short- and long-term disease state complications. Current research indicates that this trend is particularly prevalent in underserved communities lacking access to appropriate health resources.

Now, pediatric endocrinologists at UBMD Pediatrics and the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo have launched a collaboration to provide remote care management and physiological monitoring for children living with Type 1 diabetes. The team will be evaluating the financial viability of providing these services as well as their impact on diabetes-related outcomes.

A $1.43 million grant awarded to UBMD Pediatrics from The Leona M. and Harry B. Helmsley Charitable Trust is making this program possible.

Despite recognition of the benefits of remote care programs that deliver support in-between physician visits, most primary care and specialty providers lack the financial resources to deploy them effectively. Moreover, the COVID-19 pandemic has exacerbated outcome gaps among underserved communities primarily due to limited access to remote care services and community-based resources.

By working with Cecelia Health, a virtual-first health care provider, UBMD Pediatrics will be supplementing the in-person patient care it provides with care from an experienced remote diabetes and chronic care management team. Cecelia Health provides patients with a spectrum of support in managing their diabetes to ease the daily burden, help improve health outcomes, and free up care resources for providers.

A key goal of the program is to explore how improving access to remote support and the internet to better manage chronic conditions will improve outcomes. In particular, the program will examine whether access to fully supported cellular-enabled tablets and remote support enables patients to take full advantage of their existing diabetes technologies, such as continuous glucose monitors and insulin pumps. In return, this should improve HbA1c levels and reduce hospital admissions for diabetic ketoacidosis, a life-threatening condition which develops when the body doesn't have enough insulin to allow blood sugar into cells for use as energy.

Using telehealth to improve care of youth with Type 1 diabetes is at the forefront of clinical care, said Lucy Mastrandrea, MD, PhD, Associate Professor and Chief of the Division of Pediatric Endocrinology/Diabetes at the Jacobs School and UBMD Pediatrics. We expect to show that utilizing certified diabetes care and education specialists to deliver virtual support and education to our patients and families is financially sustainable. We are also taking this further by studying the clinical outcomes of patients with limited internet access who are provided tablets with cellular service and full technical support.

Our Division of Pediatric Endocrinology/Diabetes cares for about 1,000 patients with diabetes, said Kathleen Bethin, MD, PhD, principal investigator of the study and Clinical Professor of Pediatrics at the Jacobs School. We have many years of experience with both basic and clinical research to improve the lives of our patients.

Cecelia Health has worked with several university and hospital diabetes specialty clinics during the COVID-19 pandemic.

During the first year of the COVID-19 pandemic, and thanks to the support of the Helmsley Charitable Trust, we were fortunate to leverage the expertise of Cecelia Health and its team of certified diabetes care and education specialists to provide telehealth support services to our diabetes patients who were unable to be seen in-person on a regular interval, said Bethin, also a member of UBMD Pediatrics Division of Endocrinology/Diabetes.

Additionally, the researchers are interested to see how video care support along with improved ability to share data from pumps and blood glucose devices compares to phone-only support.

We are thrilled to be collaborating with UBMD Pediatrics on this important initiative, said Arnold Saperstein, MD, FACP, Chief Medical Officer at Cecelia Health. It affords us the opportunity to highlight both the clinical and financial value of our remote care model for chronic conditions in partnership with established clinical practices.

The grant will support this collaboration for three years.

Dedication to discovery, patient care, and advancing science is what defines renowned academic medical centers like ours, said Steven E. Lipshultz, MD, A. Conger Goodyear Professor and Chair of Pediatrics in the Jacobs School. UBMD Pediatrics is proud to join forces with the Helmsley Charitable Trust and Cecelia Health to transform the lives of the patients we serve by translating innovation in the lab to improve outcomes at the bedside and in the community, elevating care in an equitable and inclusive way for all patients.

The Helmsley Charitable Trust, the funder of this project, is one of the largest private foundation funders of Type 1 diabetes in the nation.

Telehealth has the unparalleled ability to meet patients where they are, but for these services to be used, they must be reimbursed properly said Sean Sullivan, PhD, Program Officer for the Helmsley Charitable Trusts Type 1 Diabetes Program. This innovative work aligns with our goal at Helmsley to better understand the impact and viability of programs that can expand access to quality care for all people with Type 1 diabetes, regardless of their zip code.

To learn more about how to support children with Type 1 diabetes through medical discovery and advances at the Jacobs School visit http://www.buffalo.edu/campaign.html or contact Kathy M. Swenson, Senior Director of Advancement at kswenson@buffalo.edu or by calling 716.829.5052.

About Cecelia Health

Cecelia Health is a virtual-first provider organization delivering integrated care to patients across all chronic disease risk profiles. We address critical care gaps, reduce variability in care, and improve medication and device adherence. Our virtual specialty care solution delivers the optimal mix of clinical interventions with digital touchpoints. We offer a comprehensive suite of synchronous and asynchronous disease management capabilities including remote clinical support, device training, remote patient monitoring, and telemedicine delivered via a national network of specialty providers. We complement our virtual care capabilities with robust data and analytics that deliver meaningful insights to our partners.

Cecelia Health Media Contact: Misty Greficz.

About UBMD Pediatrics

UBMD Pediatricsis one of 18 practice plans within UBMD Physicians Group, the single largest medical group in Western New York.We provide premier primary and specialty health care to infants, children, adolescents, and young adults throughout Western New York and beyond. Our doctors make up the academic teaching faculty within the Department of Pediatrics at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and are also the physicians at Oishei Childrens Hospital.For more information, please visit UBMDPediatrics.com.

About the Helmsley Charitable Trust

The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has committed more than $3 billion for a wide range of charitable purposes. The Helmsley Type 1 Diabetes Program is one of the largest private foundation funders of T1D in the nation focused on understanding the disease, developing better treatments, and improving care and access in the U.S and low- and middle- income countries. For more information on Helmsley and its programs, visit helmsleytrust.org.

Continue reading here:
Improving outcomes for children and adolescents living with Type 1 diabetes is the goal of a collaboration between UBMD Pediatrics and Cecelia Health...

One year ago today, WHO, together with the Government of Canada, launched the Global Diabetes Compact an ambitious new initiative to galvanize efforts around the world to both reduce the risk of diabetes, and ensure that all people diagnosed with diabetes have access to equitable, comprehensive, affordable and quality treatment and care.

Those responsible for the conception of the Compact were under no illusions about the immensity of the challenge.

The fact that 100 years after the discovery of insulin, a life-saver for many people with diabetes, the treatment was still out of reach for millions of people who needed it, was a clear signal that business as usual was no longeran option, said Dr Bente Mikkelsen, Director of the Department of Noncommunicable Diseases at the World Health Organization. The enthusiasm that we saw among political leaders at the highest levels for the Global Diabetes Compact showedus that the motivation for a radical scale-up of efforts was widely supported.

A World Health Assembly Resolution: an important milestone

The critical nature of scaling-up efforts to prevent and treat diabetes was made clear by the adoption by WHO Member States of a historic resolution on diabetes at the World Health Assembly in May. The Resolution recommends the integration of prevention and treatment of diabetes into primary health services, the development of pathways for a substantial increasein access to insulin, the promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies and improved diabetes monitoring and surveillance. Furthermore, it asks WHO to advise Member States on how to ensurethe uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.

Meanwhile work was underway to ensure that WHO had access to leading experts to provide technical advice on matters relating to WHOs work on diabetes. The result was the establishment of a Technical Advisory Group on Diabetes in August. The Group,chaired by Professor Amanda Adler, Professor of Diabetic Medicine and Health Policy at Oxford University, met for the first time in September 2021.

The importance of engaging a broader community beyond technical experts was very clear when the Compact was established, and in November, the first Global Diabetes Compact Forum was held. With more than 50 participants from nongovernmental organizations, academic institutions, philanthropicfoundations and business associations, the Forum provided an opportunity for the exchange of information on ongoing and future activities and the sharing of ideas on future endeavours that could be organized collectively for greater impact.

Learning from people with lived experience

Hearing from and learning from people living with diabetes will help ensure that work undertaken through the Compact is focused on areas where action is most needed. Focus groups hosted by WHO brought together more than 50 individuals with lived experienceearly in the year for an exchange of knowledge and information to help direct WHOs diabetes efforts. The event featured the expertise and passion of people with lived experience from over 20 countries, from Africa to the Americas to Asia, including Australia, Bosnia and Herzegovina, Brazil, Canada, Costa Rica, Ghana, India, Indonesia, Kenya, Mexico, Netherlands, Nigeria, occupied Palestinian territory, South Africa, Sweden, Tunisia, and the United States of America.During the event, facilitated by people with lived experience from Australia, Bosnia and Herzogovina, Costa Rica, India, Mexico and the UnitedStates of America. Insights were shared on access to and the affordability of diabetes care, medicine and technologies; diabetes risk reduction and education; mental health and the stigma associated with diabetes; and research and innovation.

New report recommends key actions for better accessibility of insulin

Anew reportpublished by WHO in the lead-up to World Diabetes Day in November highlighted the alarming state of global access to insulin and diabetes care, findingthat high prices, low availability of human insulin, few producers dominating the insulin market and weak health systems are the main barriers to universal access.

Recommendations made in the report for addressing these issues included boosting human insulin production, introducing pooled procurement mechanisms to bring down prices and improving transparency in price-setting. As part of efforts to address theseand other issues relating to the insulin market, WHO has embarked on dialogues with the private sector on medicines and technologies for diabetes care, the last of which was held in September 2021. While these early discussions have served as a basis for setting out goals and potential activitiesto reach them, WHO will continue to encourage and ask the private sector for commitments and contributions with the aim of dramatically improving access to insulin and health technologies in low- and middle-income countries, as well as in humanitarianemergencies.

Making a difference at country level

The establishment of the Compact and its associated coordination activities have given added impetus to diabetes efforts within ministries of health around the world.

WHO regional and country office staff have used the opportunity to support countries in their efforts, providing technical guidance and support for advocacy efforts.

World Diabetes Day in November, when there is focused attention from media and the public health community on the topic, provided an opportunity to highlight new and ongoing initiatives.

In a special ceremony at UN City in Copenhagen the day after World Diabetes Day, the World Diabetes Foundation signed an agreement granting WHO more than US$ 900 000 for a 3-year project in support of efforts for the prevention and control of noncommunicable diseases in primary care in Kyrgyzstan and Uzbekistan. The main beneficiaries of this project will be people with diabetesand their families and carers, particularly those most in need.

Also in November, at a national conference in Ljubljana, Slovenia presented its National Programme of Diabetes Control and Management 20202030. Detailed action plans will be developed every two years, with reporting required at the end of each period.

In Africa, WHO has been working hard to integrate diabetes into primary care, using the WHO Package of Essential Noncommunicable disease interventions (PEN) toolkit. Seven countries Burkina Faso, Mali, Niger, Senegal, Uganda, United Republic of Tanzania and Zimbabwe are implementing the HEARTS package. In Mali, the training of health-care workers on managing diabetes is underway. There are ongoing projects with partners such as the International Diabetes Federation, Africa Region and Sant Diabte.

In South-East Asia, WHOs technical guidance on diagnosis and management of type 2 diabetes, HEARTS-D, was adapted into an online training module for use by programme managers responsible for planning diabetes services and facility managers andprimarycare staffinvolved in clinical care.

Also in South-East Asia, donations of insulin were provided to Bhutan, Maldives, Nepal, Sri Lanka and Timor-Leste during 2021. While donations are not a sustainable solution to meeting population needs for diabetes medicines, they have enabled countriesto meet at least some of their needs during a year when supply continued to be disrupted by the COVID-19 pandemic.

Looking ahead

Reflecting on the year since the launch of the Compact and looking ahead, Dr Bente Mikkelsen said: In the past twelve months we have established the foundations that will enable us to collectively work towards the goals of the Global Diabetes Compact.But this is just the start. We look forward to building on the achievements of this first year with our partners around the world to make a real difference to the lives of people with diabetes. They are counting on us.

Follow this link:
The Global Diabetes Compact: a promising first year - World Health Organization